Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial
Last Updated: Tuesday, January 24, 2023
99mTc-PSMA single-photon emission computed tomography (SPECT)/CT was superior at detecting bone metastases in patients with prostate cancer, compared to 99mTc-methylene diphosphonate (MDP) SPECT/CT, according to data from a recent study. In particular, 99mTc-PSMA SPECT/CT was better at detecting bone metastases in patients with low PSA levels and with small lesions.
Advertisement
News & Literature Highlights